Article Listing - Par Pharma to acquire niche generics producer Anchen for $410 million

CHILE'S PROFARMA SEEKING DEALS

23 March 1992

Laboratorios Profarma is one of Chile's smaller national pharmaceutical companies, but its size is not indicative of its importance in...

MEDEVA ACQUIRES HEP-B PRODUCTS

23 March 1992

UK pharmaceuticals group Medeva is continuing its program of buying and developing pharmaceutical products with short development times with the...

GENENTECH'S DNase IN CYSTIC FIBROSIS

23 March 1992

Genentech's recombinant human deoxyribonuclease I (DNase) has been found to be safe in the treatment of cystic fibrosis patients. And...

SCHERER/FABRE DRUG DELIVERY ACCORD

23 March 1992

Pierre Fabre of France and US-based R P Scherer have entered into a collaborative agreement targeted at the development and...

GAMBRO PRETAX EARNINGS JUMP 46%

16 March 1992

Swedish company Gambro reported sales up 12.9% to 5.62 billion Swe-dish kroner ($943.8 million) for 1991, and pretax earnings of...

HOECHST DEFENDS NOMIFENSINE IN SUIT

16 March 1992

The German drugs major Hoechst AG is defending itself against allegations linked to claimed side effects of the company's antidepressant...

MEVACOR WORKS IN FDB, SAYS STUDY

16 March 1992

Familial defective apolipoprotein B-100 (FDB), an autosomal dominant disorder characterized by hyper-cholesterolemia, has been shown to be responsive to treatment...

HANTAREX BIOMED LINK WITH SMA?

16 March 1992

A new alliance with possible developments in the biomedical sector has been set up recently in Italy. Under a preliminary...

BEECHAM WITHDRAWS TALPEN FROM UK

16 March 1992

- Beecham Pharma has withdrawn the broad spectrum penicillin antibiotic Talpen (talampicillin hydrochloride) from the UK market on grounds that...

TREATMENT IND FOR AGOURON'S AG-331

16 March 1992

- Oncologists have confirmed that USA-based Agouron Phar-ma's AG-331 has been effective against tumors in animals. The company plans to...

Showing 94561-94570 of 95316 articles

Go to beginningPreviousNextGo to end